Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.61 |
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | IL1B | P01584 | 1/20 | 0.46 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25270742 | 0.95 | CRBN (0.61) | CRBNIKZF2CSNK1A1BRD4TNF | |
| SCHEMBL25010179 | 0.88 | CRBN (0.69) | CRBNIKZF2CSNK1A1BRD4TNF | |
| SCHEMBL25236602 | 0.87 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| SCHEMBL25233550 | 0.85 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| SCHEMBL31076557 | 0.84 | CRBN (0.53) | CRBNIKZF2IKZF1 | |
| SCHEMBL25272363 | 0.84 | CRBN (0.53) | CRBNIKZF2IKZF1 | |
| SCHEMBL24779145 | 0.83 | CRBN (0.63) | CRBNIKZF2CSNK1A1BRD4TNF | |
| SCHEMBL25010359 | 0.83 | CRBN (0.67) | CRBNIKZF2CSNK1A1DDB1IKZF3 | |
| SCHEMBL25010379 | 0.83 | CRBN (0.63) | CRBNIKZF2CSNK1A1BRD4TNF | |
| SCHEMBL25343190 | 0.83 | CRBN (0.67) | CRBNIKZF2CSNK1A1BRD4TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |